mRNA plus tumor lysate-loaded autologous DC vaccine therapy (Diakonos)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NamemRNA plus tumor lysate-loaded autologous DC vaccine therapy (Diakonos)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapyCell and gene therapy > Gene therapy > mRNAVaccines > Development/production technology > Dendritic cell vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsHead and Neck NeoplasmsHemangiosarcoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsYes

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesDiakonos Oncology Corp

China Registration ClassN/A

Develop Information

Active CompaniesDiakonos Oncology Corp

Inactive CompaniesN/A

Active IndicationsHead and Neck NeoplasmsHemangiosarcoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A